23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications...
16:58 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies identified a JAG2 -targeting MT-TL1 fragment that could help treat colorectal cancer. The fragment consisted of a dicer 1 ribonuclease type III (DICER1)-cleaved form of MT-TL1 and...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
20:33 , Apr 21, 2017 |  BC Week In Review  |  Clinical News

Tarextumab: Development discontinued

OncoMed said it will discontinue all clinical development of tarextumab after reporting data from 145 previously untreated patients with extensive-stage SCLC in the Phase II portion of the double-blind, placebo-controlled, U.S. Phase Ib/II PINNACLE trial...
19:00 , Apr 17, 2017 |  BC Extra  |  Clinical News

OncoMed reeling after latest Phase II failure

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) sank $0.83 (17%) to $4.01 on Monday after it said tarextumab (OMP-59R5) failed to significantly extend progression-free survival (PFS) in the Phase II PINNACLE trial as a first-line treatment for extensive-stage...
22:57 , Apr 7, 2017 |  BioCentury  |  Emerging Company Profile

Up a notch

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG ’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Notch signaling pathway; hairy and enhancer of split1 (HES1)

Cancer INDICATION: Sarcoma In vitro and mouse studies suggest inhibiting Notch signaling could help treat dedifferentiated liposarcoma. In patient tissue samples, levels of the Notch pathway ligand HES1 were higher in tumors than in normal...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Tarextumab: Completed Phase Ib/II enrollment

OncoMed completed enrollment of 145 patients with extensive-stage SCLC in the Phase II portion of the double-blind, placebo-controlled, U.S. Phase Ib/II PINNACLE trial of 15 mg/kg IV tarextumab. Patients will receive tarextumab every 3 weeks...
07:00 , Aug 18, 2016 |  BC Extra  |  Financial News

OncoMed raises $55M in follow-on

Cancer stem cell company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) raised $55 million through the sale of 5.5 million shares at $10 in a follow-on underwritten by Leerink, Wells Fargo and JMP Securities. The company proposed the...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

Tarextumab: Updated Phase Ib/II data

Updated data from 27 patients with SCLC in the dose-escalation Phase Ib portion of the international Phase Ib/II PINNACLE trial showed that IV 5-15 mg/kg tarextumab every 3 weeks plus etoposide and cisplatin for up...